Longer patents for increases generic competition in the US. The Waxman-Hatch act after one decade

PharmacoEconomics

Volumn 10, Issue SUPPL. 2, 1996, Pages 110-123

  Grabowski, Henry ^a   Vernon, John ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; CHLORPROPAMIDE; CLONIDINE; DIAZEPAM; DOXEPIN; FLURAZEPAM; GENERIC DRUG; HALOPERIDOL; IBUPROFEN; INDOMETACIN; LORAZEPAM; METHYLDOPA; METOCLOPRAMIDE; PROPRANOLOL; TOLAZAMIDE; VERAPAMIL;

COMPETITION; CONFERENCE PAPER; DRUG COST; HEALTH CARE COST; PRIORITY JOURNAL; UNITED STATES; ARTICLE; COST; COST CONTROL; ECONOMIC ASPECT; LEGAL ASPECT; LICENSING; PATENT; STATISTICS;

COST CONTROL; COSTS AND COST ANALYSIS; DRUG COSTS; DRUGS, GENERIC; ECONOMIC COMPETITION; LICENSURE; PATENTS; UNITED STATES;

EID: 0029838687     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199600102-00017     Document Type: Conference Paper

References (22)

1. Grabowski H, Vernun J. Longer patents for lower imitation barriers: the 1984 Drug Act. Am Economic Rev 1986; 76 (2): 195-8
2. Grabowski H, Vernon JM. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econ 1992; 35: 331-50
3. Mandelker J. Get the most out of your PBM. Business and Health 1994; November: 37-41
4. IMS America Inc. US drug store and hospital sales (1989 to 1993). Plymouth Meeting (PA), IMS America
5. The drugmakers vs. the trustbusters. Business Week 1994; September 5: 67
6. Greene WH. Econometric analysis. New York: McMillan, 1990
7. Caves RE, Whinston MD, Hurwitz MA. Patent expiration, entry, and competition in the US pharmaceutical industry: an exploratory analysis. Brookings Papers on Economic Activity: Microeconomics 1991. Washington DC: Brookings Institute: 1-48
8. Masson A, Steiner R. Generic substitution and prescription drug prices: economic effects of state drug product selection laws. Staff Report of the Bureau of Economics, Federal Trade Commission, Washington DC: October 1985
9. Bloom B, Wierz DJ, Pauly M. Cost and price of comparable branded and generic pharmaceuticals. JAMA 1986; 256 (18): 2523-30
10. Grabowski H, Vernon J. The regulation of pharmaceuticals: balancing the benefits and risks. Washington: American Enterprise Institute for Public Policy Research, 1983: 14-48
11. Eisman M, Wardell W. The decline in effective patent life of new drugs. Res Management 1981; 21: 18-21
12. Kaitin KI, Trimble AG. Implementation of the drug price competition and patent term restoration of 1984: a progress report. J Clin Res Drug Devel 1987; 1: 263-75
13. Shulman S, Bienz-Tadmor B, Seo PS, et al. Implementation of the Orphan Act: 1983-1991. Food and Law J 1992; 47 (4): 363-404
14. Patent and Trademark Office. Determination of new expiration dates of certain patents. Federal Register, Vol. 60, no. 109, June 7, 1995
15. Hoffmann La Roche Inc., et al. vs Bruce Lehman, vs District Court for the Eastern District of Virginia, Civil action no. 95-1236A, Alexandria, Virginia, Oct 16, 1995
16. Morrison S. Prescription drug prices: the effects of generics, formularies and other market changes. Congressional Research Service Report for Congress, August 17, 1983
17. Shaw HK. Catalysts for change: the impact of generic drugs on the pharmaceutical industry. Spectrum, Report 38, Decision Resources, Burlington, Mass: December 28, 1992
18. Grabowski H, Vernon J. Prospects for returns to pharmaceutical R&D under health care reform forthcoming. In: Helms RB, editor. Competitive strategies in the pharmaceutical industry. Washington DC: AEI Press, 1996
19. Grabowski H, Vernon J. Pioneers, imitators and generics - a simulation model of Schumpeterian competition. Q J Econom 1987; 101: 491-525
20. DiMasi J, Hansen R, Grabowski H, et al. The cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107-42
21. Hansen B, Hill C. Obtaining an SPC in Europe. Patents and Licensing 1994; Jun: 27-30
22. DiMasi J. A new look at US drug development and approval times. Tufts Center for the Study of Drug Development, Tufts University, Boston, Mass., 1996